Table 2 lists the adverse reactions recorded in the pooled 104-week NV-02B-007 GLOBE and NV- 02B-015 studies by system organ class and by frequency using the following convention: very common (≥ 1/ 10); common (≥ 1/ 100 to < 1/ 10); uncommon (≥ 1/ 1,000 to < 1/ 100); rare (≥ 1/ 10,000 to < 1/ 1,000); very rare (< 1/ 10,000).